News >

ctDNA Monitoring Carries Clinical Validity in Advanced BRAF-Mutant Melanoma

Danielle Ternyila
Published: Tuesday, Jul 23, 2019

David Polsky, MD, PhD, professor of dermatology at NYU Langone Health

David Polsky, MD, PhD

Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist), according to findings of a recent analysis that were presented at the 2019 ASCO Annual Meeting.  
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication